hmr 1766 has been researched along with Fibrosis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bauersachs, J; Fraccarollo, D; Galuppo, P; Motschenbacher, S; Ruetten, H; Schäfer, A | 1 |
1 other study(ies) available for hmr 1766 and Fibrosis
| Article | Year |
|---|---|
Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiotonic Agents; Cell Communication; Cells, Cultured; Disease Models, Animal; Drug Therapy, Combination; Enzyme Activation; Enzyme Activators; Extracellular Matrix; Fibrosis; Guanylate Cyclase; Heart Failure; Hemodynamics; Humans; Male; Mice; Mitochondria, Heart; Myocardial Contraction; Myocardial Infarction; Myocytes, Cardiac; Myofibroblasts; Nitric Oxide; Nitric Oxide Synthase Type III; ortho-Aminobenzoates; Oxidative Stress; Ramipril; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Sulfonamides; Superoxides; Time Factors; Ventricular Function, Left; Ventricular Remodeling | 2014 |